应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
02269 药明生物
未开盘 11-17 16:08:15
46.300
-0.440
-0.94%
最高
47.060
最低
45.060
成交量
2,402万
今开
46.500
昨收
46.740
日振幅
4.28%
总市值
1,906亿
流通市值
1,906亿
总股本
41.17亿
成交额
11.10亿
换手率
0.58%
流通股本
41.17亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
招银国际:医药行业估值修复行情有望延续 推荐药明生物(02269.HK)等标的
智通财经 · 11-17 11:09
招银国际:医药行业估值修复行情有望延续 推荐药明生物(02269.HK)等标的
异动解读|药明生物盘中下跌3.34%,贝莱德减持叠加板块走弱
行情直击 · 11-17 10:15
异动解读|药明生物盘中下跌3.34%,贝莱德减持叠加板块走弱
贝莱德:在药明生物的持股比例降至5.76%
格隆汇 · 11-16 17:11
贝莱德:在药明生物的持股比例降至5.76%
异动解读|药明生物盘中下跌3.11%,板块走弱下费森尤斯合作催化降温
行情直击 · 11-13
异动解读|药明生物盘中下跌3.11%,板块走弱下费森尤斯合作催化降温
【券商聚焦】中信建投:医药板块前三季度经营持续改善 创新药出海、CXO等主线值得关注
金吾财讯 · 11-13
【券商聚焦】中信建投:医药板块前三季度经营持续改善 创新药出海、CXO等主线值得关注
港股期权 | 泡泡玛特145港元认购期权成交破万张,腾讯420港元CALL交投活跃,小米38港元看涨期权受关注
老虎资讯综合 · 11-11
港股期权 | 泡泡玛特145港元认购期权成交破万张,腾讯420港元CALL交投活跃,小米38港元看涨期权受关注
异动解读|药明生物盘中下跌3.43%,板块走弱下费森尤斯合作催化降温
行情直击 · 11-11
异动解读|药明生物盘中下跌3.43%,板块走弱下费森尤斯合作催化降温
异动解读|药明生物盘中上涨3.13%,费森尤斯合作与机构看多预期持续催化
行情直击 · 11-10
异动解读|药明生物盘中上涨3.13%,费森尤斯合作与机构看多预期持续催化
【券商聚焦】招银国际:中国创新药出海BD是核心动力
金吾财讯 · 11-09
【券商聚焦】招银国际:中国创新药出海BD是核心动力
生物医药板块走强 再鼎医药(09688)涨超13% 全球医药融资回暖支撑创新药与CXO景气上行
金吾财讯 · 11-09
生物医药板块走强 再鼎医药(09688)涨超13% 全球医药融资回暖支撑创新药与CXO景气上行
异动解读|药明生物盘中上涨3.4%,费森尤斯合作与机构看多预期持续催化
行情直击 · 11-09
异动解读|药明生物盘中上涨3.4%,费森尤斯合作与机构看多预期持续催化
【港股开盘】港股开盘向好 恒指高开0.59% 药明生物(02269)涨2.90%
金吾财讯 · 11-09
【港股开盘】港股开盘向好 恒指高开0.59% 药明生物(02269)涨2.90%
异动解读|药明生物盘中下跌5.46%,短线获利回吐压制此前合作利好
行情直击 · 11-06
异动解读|药明生物盘中下跌5.46%,短线获利回吐压制此前合作利好
【券商聚焦】中信建投评26 ESMO:中国创新药持续突破,竞争与差异化并存
金吾财讯 · 11-06
【券商聚焦】中信建投评26 ESMO:中国创新药持续突破,竞争与差异化并存
药明生物更新2026年10月股份变动月报表,股本小幅增加469,403股
公告速递 · 11-05
药明生物更新2026年10月股份变动月报表,股本小幅增加469,403股
花旗:将药明生物(02269)纳入90天上行催化剂观察名单 预计第四季度或上调全年指引
智通财经 · 11-05
花旗:将药明生物(02269)纳入90天上行催化剂观察名单 预计第四季度或上调全年指引
异动解读|药明生物盘中上涨3.19%,费森尤斯大单合作持续催化
行情直击 · 11-05
异动解读|药明生物盘中上涨3.19%,费森尤斯大单合作持续催化
恒指午后走强涨超1%,创新药概念股强势拉升
老虎资讯综合 · 11-04
恒指午后走强涨超1%,创新药概念股强势拉升
CRO概念股早盘涨幅居前 凯莱英及药明生物均涨超5%
新浪港股 · 11-04
CRO概念股早盘涨幅居前 凯莱英及药明生物均涨超5%
CXO板块逆市走强 百济神州(06160)涨5.14%、凯莱英(06821)涨4.19%
金吾财讯 · 11-04
CXO板块逆市走强 百济神州(06160)涨5.14%、凯莱英(06821)涨4.19%
加载更多
公司概况
公司名称:
药明生物
所属市场:
SEHK
上市日期:
--
主营业务:
药明生物技术有限公司是一家主要从事向生物制剂行业的客户提供就生物发现、开发及生产的端到端解决方案及服务的投资控股公司。该公司主要通过两个分部运营其业务。生物药分部主要从事提供生物药的发现、开发和生产。药明合联(XDC)分部主要从事为抗体偶联药物(ADCs)及各种生物偶联药物提供合同研究、开发及生产组织(CRDMO)服务。该公司主要在国内和国外市场开展其业务。
发行价格:
--
{"stockData":{"symbol":"02269","market":"HK","secType":"STK","nameCN":"药明生物","latestPrice":46.3,"timestamp":1794902895005,"preClose":46.74,"halted":0,"volume":24015440,"delay":0,"changeRate":-0.009413778348309901,"floatShares":4117000000,"shares":4117000000,"eps":1.3661868637964991,"marketStatus":"未开盘","change":-0.44,"latestTime":"11-17 16:08:15","open":46.5,"high":47.06,"low":45.06,"amount":1109948103,"amplitude":0.04279,"askPrice":46.3,"askSize":26000,"bidPrice":46.28,"bidSize":65500,"shortable":3,"etf":0,"ttmEps":1.3941759645819112,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1794965400000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":1497283200000,"exchange":"SEHK","adjPreClose":46.74,"openAndCloseTimeList":[[1794879000000,1794888000000],[1794891600000,1794902400000]],"volumeRatio":1.0558452920519248,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"WXB.HK","impliedVol":0.3498,"impliedVolPercentile":0.1504},"requestUrl":"/m/hq/s/02269","defaultTab":"news","newsList":[{"id":"2684269678","title":"招银国际:医药行业估值修复行情有望延续 推荐药明生物(02269.HK)等标的","url":"https://stock-news.laohu8.com/highlight/detail?id=2684269678","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2684269678?lang=zh_cn&edition=full","pubTime":"2026-11-17 11:09","pubTimestamp":1794884986,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0516422440.USD","LU0307460666.USD","02269","LU0128526141.USD","LU0856984785.SGD","LU0516422952.EUR","LU0561508036.HKD","LU1242518857.USD","IE00BFMHRM44.USD","LU0348735423.USD","LU0314109678.HKD","LU0819121731.USD","LU0359201612.USD","LU0540923850.HKD","SG9999002463.SGD","LU1880383366.USD","LU0456846285.SGD","LU0417516738.SGD","LU0043850808.USD","LU0516423091.SGD","LU2476274720.SGD","LU0588546209.SGD","LU0359202008.SGD","LU1688375341.USD","LU0979878070.USD","LU1813983027.USD","LU0029874905.USD","LU1794554557.SGD","LU0052750758.USD","LU2039709279.SGD","LU1242518931.SGD","LU0128522744.USD","LU2399975544.HKD","SG9999011746.SGD","BK1521","LU0320764599.SGD","LU0051755006.USD","LU0140636845.USD","LU0823426308.USD","LU0516423174.USD","BK1610","KURE","LU1720050803.USD","LU0417516902.SGD","LU0181495838.USD","LU0229945570.USD","LU0348825331.USD","LU0029874061.USD","LU0039217434.USD","LU3063872942.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104740533","title":"异动解读|药明生物盘中下跌3.34%,贝莱德减持叠加板块走弱","url":"https://stock-news.laohu8.com/highlight/detail?id=1104740533","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1104740533?lang=zh_cn&edition=full","pubTime":"2026-11-17 10:15","pubTimestamp":1794881738,"startTime":"0","endTime":"0","summary":"11月17日,药明生物盘中下跌3.34%,报45.18港元,成交额3.48亿港元。消息面上,贝莱德披露其在药明生物的持股比例降至5.76%,构成当日股价承压的直接扰动。结合近期交易看,生命科学工具和服务板块整体偏弱,同板块内药明合联跌3.59%,金斯瑞生物-一千跌5.32%,晶泰控股跌4.43%。此前市场对费森尤斯合作、全年指引上调预期等利好已有反复交易,边际催化降温后,资金对持仓变动更为敏感。(以上内容均基于市场公开消息,由程序或算法智能生成,仅作为股价异动提醒,不作为投资建议或交易依据。)","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"药明生物盘中走低,贝莱德减持扰动","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02269"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683928406","title":"贝莱德:在药明生物的持股比例降至5.76%","url":"https://stock-news.laohu8.com/highlight/detail?id=2683928406","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2683928406?lang=zh_cn&edition=full","pubTime":"2026-11-16 17:11","pubTimestamp":1794820317,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU0320764243.SGD","LU0516422952.EUR","LU2039709279.SGD","LU0417516738.SGD","LU0543330566.HKD","LU1794554557.SGD","LU0140636845.USD","LU0708995153.HKD","LU0540923850.HKD","BK1521","IE00BFMHRM44.USD","LU1242518857.USD","LU0307460666.USD","LU1813983027.USD","LU0043850808.USD","LU0320764599.SGD","LU1880383366.USD","LU1720050803.USD","LU0327786744.USD","LU0348825331.USD","LU0051755006.USD","LU0052750758.USD","BK1589","LU0128526141.USD","LU0326950275.SGD","LU0128522744.USD","BK1610","LU0181495838.USD","LU0516423174.USD","IE00B0JY6N72.USD","02269","LU0029874905.USD","LU1688375341.USD","LU0029874061.USD","LU0979878070.USD","KURE","LU0856984785.SGD","SG9999002463.SGD","LU0348735423.USD","SG9999002562.SGD","LU0516423091.SGD","LU0417516902.SGD","LU0572944931.SGD","LU0819121731.USD","BK1576","LU0823426480.USD","LU2476274308.USD","LU0314109678.HKD","LU0456846285.SGD","LU1961090484.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150748174","title":"异动解读|药明生物盘中下跌3.11%,板块走弱下费森尤斯合作催化降温","url":"https://stock-news.laohu8.com/highlight/detail?id=1150748174","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1150748174?lang=zh_cn&edition=full","pubTime":"2026-11-13 10:45","pubTimestamp":1794537942,"startTime":"0","endTime":"0","summary":"11月13日,药明生物盘中下跌3.11%,报47.34港元,成交额3.33亿港元。消息面上,公司近期增量催化仍围绕与费森尤斯达成的长期合作及机构看多预期,但相关利好此前已被市场连续交易,当前股价回落更接近板块整体走弱。此前公司与费森尤斯签署未来10年最多37款生物类似药候选产品独家开发合作,被称为业内迄今规模最大的开发协议;花旗曾将其纳入90天上行催化剂观察名单,认为第四季度或上调整体指引,瑞银维持买入评级并给出62港元目标价。(以上内容均基于市场公开消息,由程序或算法智能生成,仅作为股价异动提醒,不作为投资建议或交易依据。)","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"药明生物午后走弱,费森尤斯合作催化降温","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02269"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683541137","title":"【券商聚焦】中信建投:医药板块前三季度经营持续改善 创新药出海、CXO等主线值得关注","url":"https://stock-news.laohu8.com/highlight/detail?id=2683541137","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2683541137?lang=zh_cn&edition=full","pubTime":"2026-11-13 08:44","pubTimestamp":1794530677,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券表示,2026年前三季度医药板块经营持续改善,2027年趋势有望延续。展望2027年,创新药海外临床与注册进入密集验证期,随着出海增加、战略联盟兴起,将面对更大的市场和更复杂的竞争环境,机遇和风险并存;CXO订单转化与上游需求回暖相互促进,AIDD进一步驱动需求上升。器械业绩拐点逐步显现,中药及医药商业关注经营修复,血制品与疫苗聚焦新品、整合及出海。建议围绕创新、国际化把握机会,同时建议加大关注边际改善主线。","market":"us","thumbnail":"https://static.szfiu.com/news/20250106/ZmQ4YWNjMjZmNDUwZDg4ZTlkYjEwZTY1NmI3NmEzMzkwOTI4OTA5.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/ZmQ4YWNjMjZmNDUwZDg4ZTlkYjEwZTY1NmI3NmEzMzkwOTI4OTA5.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1995938","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CXO","LU0823426308.USD","IBBQ","09688","09995","IE00B543WZ88.USD","02269","LU0140636845.USD","BK0276","LU0516423091.SGD","159938","LU0856984785.SGD","LU1226287529.USD","IE0008369823.USD","09939","LNGR","LU0819121731.USD","LU1242518931.SGD","WX","01801","LU0417516571.SGD","01877","159992","LU0650527681.SGD","LU2399975544.HKD","MEDX","02142","HK0000165453.HKD","LU1226288170.HKD","KCE","02616","LU0228659784.USD","LU1794554557.SGD","IE00BZ08YT58.USD","06160","09926","BK1521","601066","01093","KURE","LU0320764599.SGD","06185","01177","LU0540923850.HKD","LU0067412154.USD","06978","LU2097828714.EUR","LU2097828474.EUR","LU2242644610.SGD","LU1719994722.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178169431","title":"港股期权 | 泡泡玛特145港元认购期权成交破万张,腾讯420港元CALL交投活跃,小米38港元看涨期权受关注","url":"https://stock-news.laohu8.com/highlight/detail?id=1178169431","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1178169431?lang=zh_cn&edition=full","pubTime":"2026-11-11 12:22","pubTimestamp":1794370951,"startTime":"0","endTime":"0","summary":"一、股票期权成交量11月11日,港股上午盘三大指数集体收跌,恒生科技指数一度跌至1.5%,午间收跌1.36%,恒生指数、国企指数分别下跌0.83%及0.8%。今日港股股票期权成交量达27.88万张。","market":"us","thumbnail":"https://static.tigerbbs.com/fd680cd945fd32917c8ece66ec685e5f","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fd680cd945fd32917c8ece66ec685e5f"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02269","09992","02015","00700","01928","02513","03690","00241","09988","01810"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1144975391","title":"异动解读|药明生物盘中下跌3.43%,板块走弱下费森尤斯合作催化降温","url":"https://stock-news.laohu8.com/highlight/detail?id=1144975391","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1144975391?lang=zh_cn&edition=full","pubTime":"2026-11-11 10:27","pubTimestamp":1794364038,"startTime":"0","endTime":"0","summary":"11月11日,药明生物盘中下跌3.43%,报47.92港元,成交额3.07亿港元。从公开信息看,公司近期明确增量催化仍集中在与费森尤斯达成的长期合作及机构看多预期,但该利好已在此前连续上涨中被市场反复交易,今日股价回落更明显受到板块同步走弱影响。此前公司与费森尤斯签署未来10年最多37款生物类似药候选产品独家开发合作,被称为业内迄今规模最大的开发协议;花旗曾将其纳入90天上行催化剂观察名单,认为第四季度或上调整体指引,瑞银维持买入评级并给出62港元目标价。(以上内容均基于市场公开消息,由程序或算法智能生成,仅作为股价异动提醒,不作为投资建议或交易依据。)","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"药明生物盘中走弱,费森尤斯催化降温","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02269"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100963847","title":"异动解读|药明生物盘中上涨3.13%,费森尤斯合作与机构看多预期持续催化","url":"https://stock-news.laohu8.com/highlight/detail?id=1100963847","media":"行情直击","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1100963847?lang=zh_cn&edition=full","pubTime":"2026-11-10 09:35","pubTimestamp":1794274505,"startTime":"0","endTime":"0","summary":"11月10日,药明生物盘中上涨3.13%,报50.45港元,成交额1.09亿港元。消息面上,市场继续交易公司与费森尤斯达成的长期合作,以及机构对四季度上调指引的预期。此前双方签署未来10年最多37款生物类似药候选产品独家开发合作,被称为业内迄今规模最大的开发协议,对应原研药标价年销售额合计超3700亿欧元。与此同时,花旗已将其纳入90天上行催化剂观察名单,认为公司第四季度或上调整体指引,瑞银维持买入评级并给出62港元目标价,强化市场积极预期。(以上内容均基于市场公开消息,由程序或算法智能生成,仅作为股价异动提醒,不作为投资建议或交易依据。)","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"药明生物上涨,费森尤斯合作催化","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02269"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682876428","title":"【券商聚焦】招银国际:中国创新药出海BD是核心动力","url":"https://stock-news.laohu8.com/highlight/detail?id=2682876428","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682876428?lang=zh_cn&edition=full","pubTime":"2026-11-09 13:15","pubTimestamp":1794201346,"startTime":"0","endTime":"0","summary":"金吾财讯 | 招银国际表示,2026年三季度,海外CXO和生命科学上游公司业绩延续逐季改善趋势,收入与调整后EPS中位数增速分别达+8.3%和+13.4%。生命科学上游改善最明显,CDMO受高基数影响增速放缓,临床前与临床CRO订单增长强劲,行业普遍上调全年指引。临床CRO订单维持增长,但可靠性受关注。生物药CDMO需求仍旺盛,但高基数致增速放缓。创新药融资三季度增速放缓,但2026全年预计实质性反弹,中国创新药出海BD是核心动力。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250109/M2QyMTYxN2UxNmI4NDk2OTg5NThlNDVhNTUzNjZhZTcxMjcxMzE0NDc4MDA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/M2QyMTYxN2UxNmI4NDk2OTg5NThlNDVhNTUzNjZhZTcxMjcxMzE0NDc4MDA=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1995526","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0128526141.USD","KURE","LU0856984785.SGD","LU0181495838.USD","LU0634319403.HKD","LU0327786744.USD","LU0979878070.USD","LU0456846285.SGD","LU2399975544.HKD","HK0000306685.HKD","LU0417516902.SGD","LU0572944931.SGD","02359","LU0359202008.SGD","LU1242518931.SGD","LU0043850808.USD","LU0051755006.USD","LU0072913022.USD","BK1610","LU0348827113.USD","BK1141","LU0359201612.USD","BK1576","06821","LU0455707207.USD","03347","LU2045819591.USD","LU2039709279.SGD","01873","LU0149721374.USD","01548","01521","LU0039217434.USD","LU1046422090.SGD","LU0348825331.USD","02269","IE00BFMHRM44.USD","KCE","LU0320764599.SGD","LU0501845795.SGD","LU0540923850.HKD","LU0819121731.USD","03759","HK0000320223.HKD","06127","LU0823426308.USD","BK1191","LU0516422440.USD","LU1688375341.USD","HK0000306701.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682820601","title":"生物医药板块走强 再鼎医药(09688)涨超13% 全球医药融资回暖支撑创新药与CXO景气上行","url":"https://stock-news.laohu8.com/highlight/detail?id=2682820601","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682820601?lang=zh_cn&edition=full","pubTime":"2026-11-09 10:08","pubTimestamp":1794190084,"startTime":"0","endTime":"0","summary":"金吾财讯 | 生物医药板块走强,截至发稿,再鼎医药 涨13.07%,康诺亚-B涨7.22%,康方生物涨6.33%,科伦博泰生物涨5.36%,药明生物涨4.96%,金斯瑞生物科技涨4.48%,复宏汉霖涨4.04%。2026年上半年,全球生物科技融资、License交易、并购交易金额分别达到502亿美元、1667亿美元和960亿美元,均显著超越去年上半年,医药融资及License交易持续回暖,为医药研发提供了资金支持。","market":"other","thumbnail":"https://static.szfiu.com/news/20241108/OTEzM2QyMzQzMjc2MzA3OTk2MA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/OTEzM2QyMzQzMjc2MzA3OTk2MA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1995489","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0456846285.SGD","BK1610","159992","CXO","LU0359201612.USD","06990","02162","LU1242518931.SGD","06978","LU0181495838.USD","LU1794554557.SGD","MEDX","02269","XBI","WX","LU0348767384.USD","LU2039709279.SGD","LU2476274308.USD","161726","LU0196878994.USD","LU0561508036.HKD","LU0543330566.HKD","LU0456827905.SGD","KURE","BK4581","LU0348825331.USD","09939","LU1242518857.USD","ZLAB","LU0320764243.SGD","01548","399441","BK1588","LU0140636845.USD","LU0348784397.USD","SG9999002562.SGD","159938","IBBQ","BK1574","LU0029874061.USD","09926","LU0051755006.USD","09688","HK0000165453.HKD","BK1583","02696","BK4588","LU0516423091.SGD","LNGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158640602","title":"异动解读|药明生物盘中上涨3.4%,费森尤斯合作与机构看多预期持续催化","url":"https://stock-news.laohu8.com/highlight/detail?id=1158640602","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1158640602?lang=zh_cn&edition=full","pubTime":"2026-11-09 09:41","pubTimestamp":1794188489,"startTime":"0","endTime":"0","summary":"11月9日,药明生物盘中上涨3.4%,报49.24港元,成交额2.39亿港元。消息面上,公司此前与费森尤斯达成未来10年最多37款生物类似药候选产品独家开发合作,叠加花旗将其纳入90天上行催化剂观察名单,市场继续交易其中长期订单可见性与四季度上调指引预期。该合作被称为生物类似药领域迄今规模最大的开发协议,相关产品对应原研药标价年销售额合计超3700亿欧元;瑞银维持买入评级并给出62港元目标价,进一步强化了积极预期。(以上内容均基于市场公开消息,由程序或算法智能生成,仅作为股价异动提醒,不作为投资建议或交易依据。)","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"药明生物上涨,费森尤斯合作与看多预期催化","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02269"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682074822","title":"【港股开盘】港股开盘向好 恒指高开0.59% 药明生物(02269)涨2.90%","url":"https://stock-news.laohu8.com/highlight/detail?id=2682074822","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682074822?lang=zh_cn&edition=full","pubTime":"2026-11-09 09:25","pubTimestamp":1794187555,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股开盘向好,恒指高开0.59%,国企指数高开0.62%,恒生科技指数高开1.02%。中国生物制药高开1.96%,公司公布,附属公司正大天晴自主研发的国家1类创新药TQ-A3334“TLR7激动剂”,已于2026年美国肝病研究学会年会的最新突破性摘要平行专场,以口头报告形式公布II期临床研究结果。TQ-A3334在既往临床研究中已显示出良好的安全性和初步抗乙型肝炎病毒活性。内地股市上周五走势向下,沪综指低开低走,收市下跌1.1%,沪深两市成交额亦明显减少。","market":"fut","thumbnail":"https://static.szfiu.com/news/20210810/MTYwMGM1ZDEwYjRjZDY4ZmI3MTk0ZDEyM2Y1MWFkMjMxODA4Mzk0Mzg=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/MTYwMGM1ZDEwYjRjZDY4ZmI3MTk0ZDEyM2Y1MWFkMjMxODA4Mzk0Mzg=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1995477","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2039709279.SGD","LU1961090484.USD","LU0348827113.USD","MCHmain","LU0307460666.USD","07300","01177","LU0516423174.USD","03037","LU0314109678.HKD","LU0516423091.SGD","03419","LU0561508036.HKD","LU1242518857.USD","LU0320764243.SGD","LU0326950275.SGD","LU0634319403.HKD","LU2476274720.SGD","BK1610","BK1617","LU0229945570.USD","LU0211977185.USD","SG9999002562.SGD","LU0128526141.USD","LU0417516738.SGD","IE00BZ08YS42.EUR","LU0516422440.USD","IE00B0JY6N72.USD","LU0320764599.SGD","HK0000165453.HKD","83115","BK1521","02228","LU0051755006.USD","513600","03115","HHImain","LU2476274308.USD","LU1328277881.USD","LU2778985437.USD","BK1515","LU1880383366.USD","LU0543330566.HKD","LU0029874061.USD","LU0359201612.USD","LU0823426480.USD","LU0029874905.USD","LU0348735423.USD","82800","02800","LU0456827905.SGD","WXXWY","LU0819121731.USD","LU0417516902.SGD","BK1589","LU0856984785.SGD","LU0359202008.SGD","LU1813983027.USD","LU0128522744.USD","BK1576","02833","LU0043850808.USD","LU0140636845.USD","LU0516422366.SGD","LU0823426308.USD","LU0039217434.USD","LU0979878070.USD","BK1141","LU0572944931.SGD","LU1242518931.SGD","LU0540923850.HKD","LU2399975544.HKD","LU0348825331.USD","LU1794554557.SGD","02269","07200","IE00BFMHRM44.USD","SBHMY","BK1191","SG9999002463.SGD","LU0181495838.USD","LU0516422952.EUR","LU1720050803.USD","LU0327786744.USD","09115","IE00BZ08YT58.USD","KURE","LU0052750758.USD","LU3063872942.SGD","LU0708995153.HKD","07500","SG9999011746.SGD","HSI","LU0708995583.HKD","LU1688375341.USD","LU0456846285.SGD","IE00BZ08YR35.GBP","HSTECH","LU0588546209.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165743072","title":"异动解读|药明生物盘中下跌5.46%,短线获利回吐压制此前合作利好","url":"https://stock-news.laohu8.com/highlight/detail?id=1165743072","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1165743072?lang=zh_cn&edition=full","pubTime":"2026-11-06 09:32","pubTimestamp":1793928734,"startTime":"0","endTime":"0","summary":"11月6日,药明生物盘中下跌5.46%,报46.94港元,成交额2.97亿港元。消息面上,公司此前获花旗纳入90天上行催化剂观察名单,认为其第四季度或上调整体指引;同时,药明生物与费森尤斯达成未来10年最多37款生物类似药候选产品独家开发合作,被视为生物类似药领域迄今规模最大的开发协议。不过,相关利好已在前两个交易日推动股价连续活跃,当前回落更多反映短线资金兑现压力;从板块看,药明康德、药明合联、康龙化成等同类个股亦走弱。(以上内容均基于市场公开消息,由程序或算法智能生成,仅作为股价异动提醒,不作为投资建议或交易依据。)","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"药明生物盘中下跌,短线获利回吐压力显现","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02269"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681884019","title":"【券商聚焦】中信建投评26 ESMO:中国创新药持续突破,竞争与差异化并存","url":"https://stock-news.laohu8.com/highlight/detail?id=2681884019","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681884019?lang=zh_cn&edition=full","pubTime":"2026-11-06 08:57","pubTimestamp":1793926628,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券研究指,2026年欧洲内科肿瘤学会(European Society for Medical Oncology,ESMO)中,中国创新药在多瘤种领域全面发力,众多项目从早期探索迈入III期临床或BLA/NDA阶段。国内药企已在IO双抗及多抗、ADC、小分子靶向等赛道形成多线并进格局,III期阳性终点多点开花,持续产出具备国际竞争力的临床数据,标志着中国创新药研发不断从跟随创新迈向源头创新与全球引领的新阶段,行业发展逻辑从“fast-follow”迈入“first-in-class”与“best-in-class”并行的阶段。","market":"us","thumbnail":"https://static.szfiu.com/news/20250109/ZDNhNDUwNDVmY2U2MTcxMzU2NTcyMzcyOQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ZDNhNDUwNDVmY2U2MTcxMzU2NTcyMzcyOQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1995351","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142","LU2488822045.USD","01177","KCE","01801","LU1242518931.SGD","LU1226287529.USD","LU1242518857.USD","LU1960683339.HKD","LU0516422952.EUR","LU0540923850.HKD","LU0315179316.USD","09926","LU0348766576.USD","LU0417516571.SGD","LU1813983027.USD","LU0455707207.USD","BK1515","LU0456827905.SGD","01877","LU2097828474.EUR","IE00BPRC5H50.USD","06185","LU0634319403.HKD","LU2097828714.EUR","01093","LU1188198961.HKD","LU0708995153.HKD","LU0594300179.USD","LU2242644610.SGD","02269","BK1574","LU0348783233.USD","LU0823426308.USD","601066","LU1807302812.USD","09995","02616","LU1152091168.USD","09688","BK1191","LU0228659784.USD","LU0039217434.USD","LU1251922891.USD","06160","LU1152091754.HKD","LU0128522744.USD","KURE","BK1583","LU0320764243.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192704349","title":"药明生物更新2026年10月股份变动月报表,股本小幅增加469,403股","url":"https://stock-news.laohu8.com/highlight/detail?id=1192704349","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1192704349?lang=zh_cn&edition=full","pubTime":"2026-11-05 16:52","pubTimestamp":1793868775,"startTime":"0","endTime":"0","summary":"根据药明生物于2026年11月5日发布的截至2026年10月31日止当月股份变动月报表信息,公司在报告期内就已发行股份进行更新披露。公司本月并未对法定/注册股本进行增减变动,法定/注册股本维持在6,000,000,000股普通股不变,每股面值为0.000008333333美元,总面值为5万美元。上述新发行股份主要来自公司首次公开发售前购股权计划下的行权。当月公司因购股权行权获得资金合计14.93万美元。截至10月末,公司股本总数为4,117,231,853股,较上月小幅增加,股本结构总体稳定。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02269"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681136015","title":"花旗:将药明生物(02269)纳入90天上行催化剂观察名单 预计第四季度或上调全年指引","url":"https://stock-news.laohu8.com/highlight/detail?id=2681136015","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681136015?lang=zh_cn&edition=full","pubTime":"2026-11-05 10:37","pubTimestamp":1793846253,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,花旗发布研报称,将药明生物(02269)纳入90天上行催化剂观察名单。该行认为,公司可能于第四季度上调整体指引,而与费森尤斯达成的生物相似药开发协议,亦可能促使公司上调合同生产组织(CMO)收入的长期目标。花旗表示,药明生物亦是其偏好的AI驱动药物研发(AIDD)受惠股,认为公司的AIDD能力正被市场低估。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1518833.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0106831901.USD","LU0359202008.SGD","LU2417539215.USD","LU0516422952.EUR","LU0588546209.SGD","LU0856984785.SGD","LU0314109678.HKD","LU0128526141.USD","IE00B0JY6N72.USD","LU0052756011.USD","LU0708995153.HKD","LU1791807156.HKD","LU0359201612.USD","LU0203347892.USD","TFNS","LU0516422366.SGD","LU1988902786.USD","IYF","LU1242518857.USD","LU1688375341.USD","LU0980610538.SGD","LU0128525689.USD","LU0516423174.USD","LU1267930227.SGD","LU2236285917.USD","LU2360032135.SGD","LU0516422440.USD","LU3063872942.SGD","LU0130517989.USD","LU0039217434.USD","FTXO","LU0417516738.SGD","KURE","LU0516423091.SGD","LU0128522744.USD","LU0162691827.USD","02269","BK4566","LU0417516902.SGD","BK4588","LU0307460666.USD","LU0477156953.USD","BK4207","LU0819121731.USD","LU0170899867.USD","LU1064131342.USD","LU0098860793.USD","LU2125154935.USD","LU0029874061.USD","LU0320764599.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179867353","title":"异动解读|药明生物盘中上涨3.19%,费森尤斯大单合作持续催化","url":"https://stock-news.laohu8.com/highlight/detail?id=1179867353","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1179867353?lang=zh_cn&edition=full","pubTime":"2026-11-05 09:54","pubTimestamp":1793843681,"startTime":"0","endTime":"0","summary":"11月5日,药明生物盘中上涨3.19%,报50.05港元,成交额6.03亿港元。消息面上,公司此前与费森尤斯达成独家开发协议,后者将在未来10年获得最多37款已确定生物类似药候选产品的独家选择权,成为股价持续活跃的核心催化。该合作被称为生物类似药领域迄今规模最大的开发协议,相关产品对应原研药标价年销售额合计超3700亿欧元;协议采用服务付费模式,市场普遍认为有助于强化公司中长期订单可见性。另有机构维持买入评级,目标价62港元。(以上内容均基于市场公开消息,由程序或算法智能生成,仅作为股价异动提醒,不作为投资建议或交易依据。)","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"药明生物上涨,费森尤斯大单催化","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02269"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118961689","title":"恒指午后走强涨超1%,创新药概念股强势拉升","url":"https://stock-news.laohu8.com/highlight/detail?id=1118961689","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1118961689?lang=zh_cn&edition=full","pubTime":"2026-11-04 13:39","pubTimestamp":1793770784,"startTime":"0","endTime":"0","summary":"11月4日,恒指午后走强涨超1%,创新药概念股强势拉升,$药明生物(02269)$、$药明康德(02359)$涨超9%,$荣昌生物(09995)$、$百济神州(ONC)$涨超8%,$药明合联(02268)$涨超7%,$信达生物(01801)$、$康方生物(09926)$涨超5%。","market":"hk","thumbnail":"https://static.tigerbbs.com/5d8fb95e65f042f352c6313989391357","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/5d8fb95e65f042f352c6313989391357"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999002463.SGD","LU0314109678.HKD","LU0501845795.SGD","LU0650527681.SGD","HSI","LU2488822045.USD","LU1961090484.USD","BK4139","LU0456827905.SGD","IE00BFMHRM44.USD","HK0000165453.HKD","LU0456846285.SGD","LU2242644610.SGD","SG9999011746.SGD","83115","SG9999002562.SGD","LU0588546209.SGD","LU2097828631.EUR","LU1770034418.SGD","BK1161","LU2778985437.USD","LU3063872942.SGD","BK4588","LU2097828714.EUR","LU0516422366.SGD","LU1794554557.SGD","LU1481107354.HKD","BK1588","LU0348783233.USD","02268","BK4526","LU0320764243.SGD","03115","LU0594300179.USD","LU2097828557.USD","MCHmain","IE00BPRC5H50.USD","LU0149534421.HKD","LU1969619763.USD","LU2097828805.USD","LU0128522744.USD","LU0348827113.USD","LU2097828474.EUR","82800","LU0211977185.USD","MEDX","07200","LU0359201612.USD","LU1813983027.USD","LU0417516902.SGD","LU1688375341.USD","LU0029874905.USD","02269","LU2399975544.HKD","03037","LU0043850808.USD","07300","06978","IBBQ","159992","LU0244354667.USD","KURE","LU0149721374.USD","BK1576","HHImain","LU0072913022.USD","LU0326950275.SGD","06160","LU0039217434.USD","BK1610","LU0516423091.SGD","LU1880383366.USD","LU0417516738.SGD","LU0051755006.USD","LU1303224171.USD","ONC","02359","LU0052750758.USD","LU0516423174.USD","LU1242518857.USD","LU0502904849.HKD","LU0572944931.SGD","LU0605514214.HKD","LU0634319403.HKD","LU0128526141.USD","LU0229945570.USD","LU0823426480.USD","LU0348784397.USD","IE00B5MMRT66.SGD","LU0469268626.HKD","LU1831875114.USD","LU0417516571.SGD","LU0516422440.USD","BK1589","02833","MHImain","07500","LU2045819591.USD","LU0228659784.USD","513600","LU2039709279.SGD","LU1719994722.HKD","BK1574","LU0819121731.USD","LU0463099449.HKD","SG9999014674.SGD","LU1046422090.SGD","LU0561508036.HKD","LU0856984785.SGD","LU0708995153.HKD","LU0029874061.USD","LU0543330566.HKD","LU1720050803.USD","LU0181495838.USD","01801","LU2125910500.SGD","LU1328277881.USD","LU0320764599.SGD","LU0348766576.USD","03419","BK1583","09115","LU0140636845.USD","LU0164880469.USD","IE00B543WZ88.USD","LU0348735423.USD","LU0307460666.USD","LU2476274720.SGD","LU0327786744.USD","BK1521","LU0359202008.SGD","LU0540923850.HKD","LU1188198961.HKD","HSImain","LU0708995583.HKD","02800","BK1141","IE00B0JY6N72.USD","LU0455707207.USD","09926","LU2328871848.SGD","LU0823426308.USD","BK4585","LU0348825331.USD","LU1251922891.USD","LU2476274308.USD","LU1242518931.SGD","LU0607220059.USD","09995","BK1500","LU0828237510.HKD","LU0979878070.USD","LNGR","LU0348767384.USD","LU0516422952.EUR","LU0594300419.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680088259","title":"CRO概念股早盘涨幅居前 凯莱英及药明生物均涨超5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2680088259","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680088259?lang=zh_cn&edition=full","pubTime":"2026-11-04 11:32","pubTimestamp":1793763120,"startTime":"0","endTime":"0","summary":"热点栏目自选股\n数据中心\n行情中心\n资金流向\n模拟交易客户端CRO概念股早盘涨幅居前,截至发稿,凯莱英(06821)上涨5.77%,报113.60港元;药明生物(02269)上涨5.20%,报45.30港元;药明康德(02359)上涨5.28%,报185.30港元;康龙化成(03759)上涨3.39%,报26.88港元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-11-04/doc-inixpvva1659648.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0359202008.SGD","LU3063872942.SGD","LU0181495838.USD","LU1961090484.USD","LU2476274308.USD","LU0456846285.SGD","LU0979878070.USD","BK1610","LU0029874061.USD","LU0823426308.USD","IE00B0JY6N72.USD","LU0320764599.SGD","LU0561508036.HKD","LU0229945570.USD","LU0456827905.SGD","LU0307460666.USD","LU0326950275.SGD","LU0543330566.HKD","BK1576","BK0239","LU0516422952.EUR","LU0819121731.USD","BK1141","KURE","002821","LU0348827113.USD","LU0128522744.USD","LU0327786744.USD","06821","LU0348735423.USD","LU0708995583.HKD","02269","LU0417516902.SGD","LU1880383366.USD","LU0516422366.SGD","LU1328277881.USD","LU0634319403.HKD","LU0359201612.USD","LU0516423174.USD","IE00BFMHRM44.USD","LU0051755006.USD","LU0516423091.SGD","BK1191","SG9999002463.SGD","LU1720050803.USD","LU0052750758.USD","LU2039709279.SGD","LU2476274720.SGD","LU0823426480.USD","LU2399975544.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680519700","title":"CXO板块逆市走强 百济神州(06160)涨5.14%、凯莱英(06821)涨4.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2680519700","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680519700?lang=zh_cn&edition=full","pubTime":"2026-11-04 10:34","pubTimestamp":1793759693,"startTime":"0","endTime":"0","summary":"金吾财讯 | CXO板块逆市走强,百济神州 涨5.14%,凯莱英涨4.19%,药明康德涨3.92%,药明生物涨3.58%,科伦博泰生物涨2.89%,药明合联涨2.44%,和铂医药-B涨1.76%,康龙化成涨1.46%,和黄医药涨1.17%。湘财证券表示,CXO龙头药明康德三季报超预期、指引上修,印证CXO由周期修复转向CRDMO结构性重估。维持药品行业“买入”评级,建议关注创新化学制剂及创新药产业链上游CXO公司。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250110/MjA1YmE2ZTUwNGJlNDY3ODMxMDE0ODI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/MjA1YmE2ZTUwNGJlNDY3ODMxMDE0ODI=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1995187","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0132","06821","688235","LU0455707207.USD","LU0502904849.HKD","03759","06160","06990","LU0043850808.USD","LU2476274308.USD","LU0501845795.SGD","BK1141","002821","LU0823426308.USD","ONC","LU0072913022.USD","WX","LU0823426480.USD","LU0456827905.SGD","CXO","SG9999002463.SGD","02269","02359","LU1719994722.HKD","LU0359202008.SGD","LU1720050803.USD","LU2045819591.USD","BK1574","LU0326950275.SGD","LU2476274720.SGD","LU0516422440.USD","LU0516423091.SGD","LU0128526141.USD","SG9999002562.SGD","LU0128522744.USD","LU0828237510.HKD","LU3063872942.SGD","LU0463099449.HKD","LU0348766576.USD","02142","KURE","LU0229945570.USD","LU0320764243.SGD","LU0588546209.SGD","LU1242518857.USD","LU1831875114.USD","00013","LU0327786744.USD","02268","LU0051755006.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.wuxibiologics.com","stockEarnings":[{"period":"1week","weight":-0.0669},{"period":"1month","weight":-0.0394},{"period":"3month","weight":-0.0334},{"period":"6month","weight":0.4099},{"period":"1year","weight":0.4308},{"period":"ytd","weight":0.4726}],"compareEarnings":[{"period":"1week","weight":-0.0427},{"period":"1month","weight":-0.0281},{"period":"3month","weight":-0.0779},{"period":"6month","weight":-0.074},{"period":"1year","weight":-0.109},{"period":"ytd","weight":-0.0828}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"药明生物技术有限公司是一家主要从事向生物制剂行业的客户提供就生物发现、开发及生产的端到端解决方案及服务的投资控股公司。该公司主要通过两个分部运营其业务。生物药分部主要从事提供生物药的发现、开发和生产。药明合联(XDC)分部主要从事为抗体偶联药物(ADCs)及各种生物偶联药物提供合同研究、开发及生产组织(CRDMO)服务。该公司主要在国内和国外市场开展其业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.777778,"avgChangeRate":0.052868},{"month":2,"riseRate":0.555556,"avgChangeRate":0.006907},{"month":3,"riseRate":0.555556,"avgChangeRate":-0.001977},{"month":4,"riseRate":0.444444,"avgChangeRate":-0.000488},{"month":5,"riseRate":0.555556,"avgChangeRate":0.002485},{"month":6,"riseRate":0.666667,"avgChangeRate":0.061606},{"month":7,"riseRate":0.7,"avgChangeRate":0.085288},{"month":8,"riseRate":0.6,"avgChangeRate":0.053299},{"month":9,"riseRate":0.7,"avgChangeRate":0.065466},{"month":10,"riseRate":0.4,"avgChangeRate":-0.050911},{"month":11,"riseRate":0.5,"avgChangeRate":0.027117},{"month":12,"riseRate":0.555556,"avgChangeRate":0.009161}],"exchange":"SEHK","name":"药明生物","nameEN":"WUXI BIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.54.0","shortVersion":"4.54.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"药明生物(02269)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供药明生物(02269)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"药明生物,02269,药明生物股票,药明生物股票老虎,药明生物股票老虎国际,药明生物行情,药明生物股票行情,药明生物股价,药明生物股市,药明生物股票价格,药明生物股票交易,药明生物股票购买,药明生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"药明生物(02269)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供药明生物(02269)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}